Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the lack of any candidates in Phase 3 clinical trials, per ClinicalTrials.gov registries and CDC/WHO statements confirming no licensed vaccines exist. A recent multi-country hantavirus outbreak linked to the MV Hondius cruise ship—eight cases (six confirmed) and three deaths reported by WHO as of May 8—has accelerated preclinical efforts by Moderna, University of Bath researchers developing a stable mRNA antigen, and US Army Phase 1 completers, yet experts emphasize full trials could span a decade absent Operation Warp Speed-scale funding. Hantavirus pulmonary syndrome's 50% fatality stems from sporadic rodent-borne transmission, historically impeding progress; watch for CDC outbreak updates and trial initiations.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$83,355 वॉल्यूम
$83,355 वॉल्यूम
31 दिस, 2026
$83,355 वॉल्यूम
$83,355 वॉल्यूम
31 दिस, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the lack of any candidates in Phase 3 clinical trials, per ClinicalTrials.gov registries and CDC/WHO statements confirming no licensed vaccines exist. A recent multi-country hantavirus outbreak linked to the MV Hondius cruise ship—eight cases (six confirmed) and three deaths reported by WHO as of May 8—has accelerated preclinical efforts by Moderna, University of Bath researchers developing a stable mRNA antigen, and US Army Phase 1 completers, yet experts emphasize full trials could span a decade absent Operation Warp Speed-scale funding. Hantavirus pulmonary syndrome's 50% fatality stems from sporadic rodent-borne transmission, historically impeding progress; watch for CDC outbreak updates and trial initiations.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
बाज़ार खुला: May 4, 2026, 10:39 AM ET
वॉल्यूम
$83,355समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the lack of any candidates in Phase 3 clinical trials, per ClinicalTrials.gov registries and CDC/WHO statements confirming no licensed vaccines exist. A recent multi-country hantavirus outbreak linked to the MV Hondius cruise ship—eight cases (six confirmed) and three deaths reported by WHO as of May 8—has accelerated preclinical efforts by Moderna, University of Bath researchers developing a stable mRNA antigen, and US Army Phase 1 completers, yet experts emphasize full trials could span a decade absent Operation Warp Speed-scale funding. Hantavirus pulmonary syndrome's 50% fatality stems from sporadic rodent-borne transmission, historically impeding progress; watch for CDC outbreak updates and trial initiations.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
वॉल्यूम
$83,355समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus on Polymarket assigns an 89% implied probability to no FDA-approved hantavirus vaccine by December 31, 2026, driven by the lack of any candidates in Phase 3 clinical trials, per ClinicalTrials.gov registries and CDC/WHO statements confirming no licensed vaccines exist. A recent multi-country hantavirus outbreak linked to the MV Hondius cruise ship—eight cases (six confirmed) and three deaths reported by WHO as of May 8—has accelerated preclinical efforts by Moderna, University of Bath researchers developing a stable mRNA antigen, and US Army Phase 1 completers, yet experts emphasize full trials could span a decade absent Operation Warp Speed-scale funding. Hantavirus pulmonary syndrome's 50% fatality stems from sporadic rodent-borne transmission, historically impeding progress; watch for CDC outbreak updates and trial initiations.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न